

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ALLGEIER ET AL.

APPLICATION NO: HERewith

FILED: HERewith

FOR: MGLUR5 ANTAGONISTS FOR THE TREATMENT
OF PAIN AND ANXIETYAssistant Commissioner for Patents
Washington, D.C. 20231PRELIMINARY AMENDMENT

Sir:

Prior to calculation of the filing fees, please amend the application as follows:

IN THE SPECIFICATION

Page 1, directly beneath the title; please insert the following paragraph - This is a continuation of International Application No. PCT/EP 99/07239, filed September 30, 1999, the contents of which are incorporated herein by reference. --

IN THE CLAIMS

Please amend Claims 13-18 as follows:

13. (amended) A use according to claim 9, whereby the mGluR antagonist is a specific mGluR5 antagonist.

14. (amended) A use according to claim 9, whereby predominant interaction at peripheral receptors is achieved by using a mGluR antagonist, which does not substantially penetrate the CNS.

15. (amended) A use according to claim 9, whereby predominant interaction at peripheral receptors is achieved by using a mGluR antagonist which does not substantially cross the blood-brain barrier.